U.S. Moves to End Funding for Deadly Drug Test Strips

The Trump administration has moved to stop federal support for drug-testing strips, a decision that lands in the middle of a still-raging overdose crisis.

In a letter to states and other grant recipients, the administration said it will no longer pay for strips used to detect dangerous substances in street drugs, according to reports. The stated rationale cuts to the center of a long-running political fight over harm reduction: officials argue the strips encourage drug use. Public health advocates and many local programs have long treated the tools very differently, seeing them as a low-cost way to help people avoid accidental poisoning.

The fight over test strips is really a fight over what kind of drug policy the federal government wants to pursue: punishment, prevention, or some uneasy mix of both.

The change matters because these strips have become a visible part of overdose-response strategies in many communities. Reports indicate states, nonprofits, and local health programs have used federal grant money to distribute them alongside other interventions aimed at reducing deaths. Pulling that support does not ban the strips outright, but it could force cash-strapped programs to scale back distribution or scramble for new funding.

The policy also signals a broader shift in tone. For years, harm reduction has gained ground in parts of the public health system, even as it remained politically contentious. This move suggests the administration wants to draw a harder line, one that favors deterrence over practical risk reduction. Supporters may see that as a moral and strategic correction; critics will likely argue it ignores how people actually die in the current drug supply, where contamination and unpredictability drive fatal outcomes.

What happens next will likely unfold state by state and grant by grant. Some jurisdictions may replace the lost funding with their own dollars or private support, while others may cut back quickly. The larger question reaches beyond one tool: whether federal health policy will continue to back measures designed to keep people alive in the short term, even when those measures sit inside a deeply polarizing debate over drugs, responsibility, and public safety.